Personal information

Countries

China

Activities

Collapse all

Employment (1)

Shanghai Institute of Materia Medica: Pudong, CN

2004-07-01 to present
Employment
Source: Self-asserted source
Zhen Wang

Works (9)

Absorption, distribution, metabolism, and excretion of [<sup>14</sup>C]TPN729 after oral administration to rats.

Xenobiotica; the fate of foreign compounds in biological systems
2022-01-27 | Journal article
DOI: 10.1080/00498254.2022.2030504
PMID: 35038952
Source: Self-asserted source
Zhen Wang

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects

Drug Design, Development and Therapy
2021-07 | Journal article
DOI: 10.2147/dddt.s308610
Part of ISSN: 1177-8881
Source: Self-asserted source
Zhen Wang

Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma.

Journal of pharmaceutical and biomedical analysis
2020-09-17 | Journal article
DOI: 10.1016/j.jpba.2020.113634
PMID: 32987249
Source: Self-asserted source
Zhen Wang

Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor.

Acta pharmacologica Sinica
2020-06-24 | Journal article
DOI: 10.1038/s41401-020-0447-x
PMID: 32581257
Source: Self-asserted source
Zhen Wang
grade
Preferred source (of 2)‎

Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.

Journal of medicinal chemistry
2019-05-08 | Journal article
DOI: 10.1021/acs.jmedchem.9b00123
PMID: 31021628
Source: Self-asserted source
Zhen Wang

Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

Journal of pharmaceutical and biomedical analysis
2019-05-01 | Journal article
DOI: 10.1016/j.jpba.2019.05.001
PMID: 31079024
Source: Self-asserted source
Zhen Wang

Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.

Journal of pharmaceutical and biomedical analysis
2017-12-30 | Journal article
DOI: 10.1016/j.jpba.2017.12.057
PMID: 29310052
Source: Self-asserted source
Zhen Wang
grade
Preferred source (of 3)‎

Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

Journal of pharmaceutical and biomedical analysis
2015-09-03 | Journal article
DOI: 10.1016/j.jpba.2015.09.001
PMID: 26366939
Source: Self-asserted source
Zhen Wang

The selectivity and potency of the new PDE5 inhibitor TPN729MA.

The journal of sexual medicine
2013-08-12 | Journal article
DOI: 10.1111/jsm.12285
PMID: 23937247
Source: Self-asserted source
Zhen Wang
How many people are using ORCID?